Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(71.4%)

N/A

1(14.3%)

Phase 1

1(14.3%)

7Total

Phase 2(5)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07229846Phase 2Not Yet Recruiting

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Role: lead

NCT04420130Not ApplicableWithdrawn

A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）

Role: lead

NCT04298320Phase 1Unknown

A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）

Role: lead

NCT03825328Phase 2Unknown

A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )

Role: lead

NCT03793725Phase 2Unknown

A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC

Role: lead

NCT03132025Phase 2Unknown

Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer

Role: lead

NCT01641783Phase 2Unknown

Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients

Role: lead

All 7 trials loaded